SGLT2 inhibitor-induced glucosuria improved beta-cell function and insulin sensitivity, decreased tissue glucose disposal and increased EGP following administration, thereby reducing fasting and postprandial glycemic [35]. Here, SLC5A2 is linked to Glycosuria.